Arthex Biotech Raises €11 Million to Advance Against Muscular Dystrophy

Arthex Biotech raises capital. The Spanish biotech company specializing in the treatment of diseases with unmet medical needs has raised eleven million euros from the European Investment Bank (EIB), according to Beatriz Llamusí, co-founder of Arthex Biotech.

This injection is in addition to the grant, in the form of non-dilutive financing, of €2.5 million that the company has already received from the European Commission, through the EIC Accelerator.

In parallel, the company is in negotiations so that the resources obtained reach, in total, €40 million. To do that, Arthex Biotech would give entry to between two and three new investors.

With the resources,  the company will be able to continue advancing the development of its main product, the drug ATX-01, aimed at treating myotonic dystrophy type 1 (DM1), a serious disease with no known cure or currently available drug treatment. It is a rare muscular dystrophy.

If you want to find more details about Arthex Biotech and to read the most important financial news of the day, download for free our companion app Born2Invest.

Arthex Biotech intends to give entry to more investors 

Last year, the US Food and Drug Administration (FDA) designated ATX-01 as an orphan drug. DM1 is a highly disabling disease that affects more than one million people worldwide. The condition affects the muscles and other tissues and manifests itself more frequently during advanced ages, although it can develop at birth congenitally or during childhood.

Arthex Biotech is a spin-off of the University of Valencia (UV). Established in September 2019, the company focuses on the development of a treatment for myotonic dystrophy based on antisense RNA therapies for the treatment of DM1. 

The researchers Rubén Artero and Beatriz Llamusí founded the company with the support of the capital Invivo Ventures, which committed €2.7 million so that an RNA therapy developed by the translational genomics research group of the UV and the Research Institute Sanitaria Incliva could reach DM1 patients. 

In 2020, the company closed a round of financing of €4.2 million that was led by the fund specialized in the life sciences sector Advent France Biotechnology (AFB) and Invivo Ventures, a venture capital manager from Barcelona.

__

(Featured image by TBIT via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.